GENZYME CEREDASE LOWEST EFFECTIVE DOSE MUST BE DETERMINED, NIH TECHNOLOGY ASSESSMENT PANEL SAYS; PATIENT REGISTRY RECOMMENDED FOR GAUCHER PATIENTS
Executive Summary
The National Institutes of Health should become more directly involved in seeking the lowest effective dose for Genzyme's two Gaucher disease therapies, Ceredase and Cerezyme, an NIH Gaucher Disease Consensus Conference Technology Assessment Panel concluded March 1.